Russell Investments Group Ltd. lessened its stake in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 56.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 19,970 shares of the biotechnology company’s stock after selling 25,496 shares during the period. Russell Investments Group Ltd. owned 0.07% of Five Prime Therapeutics worth $817,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc grew its position in Five Prime Therapeutics by 3.1% in the 2nd quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 287 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Five Prime Therapeutics by 1.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock valued at $646,000 after acquiring an additional 397 shares in the last quarter. Rhumbline Advisers grew its position in Five Prime Therapeutics by 1.4% in the 2nd quarter. Rhumbline Advisers now owns 34,282 shares of the biotechnology company’s stock valued at $1,032,000 after acquiring an additional 484 shares in the last quarter. Cornerstone Capital Management Holdings LLC. grew its position in Five Prime Therapeutics by 3.0% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,227 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 494 shares in the last quarter. Finally, Voya Investment Management LLC grew its position in shares of Five Prime Therapeutics by 9.5% during the second quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock worth $379,000 after buying an additional 1,097 shares in the last quarter. Institutional investors and hedge funds own 83.66% of the company’s stock.
In other news, Director William R. Ringo sold 600 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total transaction of $27,198.00. Following the completion of the sale, the director now owns 600 shares in the company, valued at $27,198. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.50% of the stock is owned by corporate insiders.
A number of equities analysts have recently commented on FPRX shares. Royal Bank of Canada boosted their price objective on Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 6th. BidaskClub downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 target price for the company in a research note on Monday, October 16th. BMO Capital Markets upgraded Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, October 16th. Finally, ValuEngine cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $64.00.
Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) opened at $21.19 on Tuesday. Five Prime Therapeutics Inc has a 52 week low of $19.73 and a 52 week high of $50.80. The firm has a market capitalization of $613.61, a P/E ratio of -4.18 and a beta of 3.90.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The company had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. During the same quarter last year, the company earned ($0.72) EPS. Five Prime Therapeutics’s revenue for the quarter was up 24.7% compared to the same quarter last year. analysts expect that Five Prime Therapeutics Inc will post -5.56 earnings per share for the current fiscal year.
WARNING: “Five Prime Therapeutics Inc (NASDAQ:FPRX) Position Trimmed by Russell Investments Group Ltd.” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://ledgergazette.com/2018/01/16/russell-investments-group-ltd-has-817000-stake-in-five-prime-therapeutics-inc-fprx.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.